Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Pancreatic Cancer | Research

Prognostic significance of preoperative lymphocytes, albumin, and neutrophils (LANR) index in resectable pancreatic ductal adenocarcinoma

Authors: Jiaru Zhuang, Shan Wang, Yuan Wang, Yibo Wu, Renjing Hu

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Purpose

The index composed of preoperative lymphocytes, albumin, and neutrophils (LANR), a new composite score based on inflammatory response and nutritional status, has been reported to be associated with the prognosis of multiple types of cancer, but the role of LANR in the prognosis of resectable pancreatic ductal adenocarcinoma (PDAC) has not yet been elucidated.

Patients and methods

The data of 142 patients with PDAC who underwent radical resection in the Affiliated Hospital of Jiangnan University from January 2015 to December 2018 were retrospectively analyzed. Receiver Operating Characteristic (ROC) curves were generated to determine the optimal cut-off values for these parameters, as well as the sensitivity and specificity of LANR in predicting survival. The Kaplan–Meier method was used to draw the survival curves. Log rank test was used for univariate analysis, and Cox proportional hazards regression model was used for multivariate analysis. 

Results

The optimal cut-off value of LANR was 18.145, and a low preoperative LANR was significantly correlated with the location of the tumor (p = 0.047). Multivariate analysis showed that tumor differentiation degree (HR:2.357, 95%CI:1.388–4.003,p = 0.002), lymph node metastasis (HR:1.755, 95%CI: 1.115–2.763, p = 0.015), TNM stage (HR:4.686, 95%CI: 2.958–7.425, p < 0.001), preoperative cancer antigen 19 − 9 levels (HR:1.001, 95%CI: 1.000-1.001, p < 0.001) and preoperative LANR (HR:0.221, 95%CI: 0.111–0.441, p < 0.001) were independent risk factors for a poor prognosis in patients undergoing radical resection of PDAC.

Conclusion

This study found that preoperative LANR can be used to assess the prognosis of radical resection in patients with PDAC; those with low preoperative LANR had a worse outcome.
Literature
1.
Latenstein AEJ, van der Geest LGM, Bonsing BA, Groot Koerkamp B, Haj Mohammad N, de Hingh I, et al. Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. Eur J Cancer. 2020;125:83–93.CrossRefPubMed
2.
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21.CrossRefPubMed
3.
Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin. 2020;70(5):375–403.CrossRefPubMedPubMedCentral
4.
5.
Kulemann B, Hoeppner J, Wittel U, Glatz T, Keck T, Wellner UF, et al. Perioperative and long-term outcome after standard pancreaticoduodenectomy, additional portal vein and multivisceral resection for pancreatic head cancer. J Gastrointest Surg. 2015;19(3):438–44.CrossRefPubMed
6.
Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267.CrossRefPubMedPubMedCentral
7.
Groot VP, Gemenetzis G, Blair AB, Rivero-Soto RJ, Yu J, Javed AA, et al. Defining and Predicting Early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg. 2019;269(6):1154–62.CrossRefPubMed
8.
Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O’Reilly EM et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023.
9.
Tong Z, Liu Y, Ma H, Zhang J, Lin B, Bao X, et al. Development, Validation and Comparison of Artificial Neural Network Models and Logistic Regression models Predicting Survival of Unresectable Pancreatic Cancer. Front Bioeng Biotechnol. 2020;8:196.CrossRefPubMedPubMedCentral
10.
Caputo D, Quagliarini E, Coppola A, La Vaccara V, Marmiroli B, Sartori B, et al. Inflammatory biomarkers and nanotechnology: new insights in pancreatic cancer early detection. Int J Surg. 2023;109(10):2934–40.CrossRefPubMedPubMedCentral
11.
Zhou T, Man Q, Li X, Xie Y, Hou X, Wang H, et al. Artificial intelligence-based comprehensive analysis of immune-stemness-tumor budding profile to predict survival of patients with pancreatic adenocarcinoma. Cancer Biol Med. 2023;20(3):196–217.CrossRefPubMedPubMedCentral
12.
Yugawa K, Maeda T, Nagata S, Sakai A, Taketani K, Yamaguchi S, et al. A novel combined carbohydrate antigen 19 – 9 and lymphocyte-to-monocyte ratio score can predict early recurrence of resectable pancreatic ductal adenocarcinoma. Surg Today. 2023;53(10):1199–208.CrossRefPubMed
13.
Chen Q, Yin H, Liu S, Shoucair S, Ding N, Ji Y et al. Prognostic value of tumor-associated N1/N2 neutrophil plasticity in patients following radical resection of pancreas ductal adenocarcinoma. J Immunother Cancer. 2022;10(12).
14.
Nurmi AM, Mustonen H, Haglund C, Seppanen H. Changes in CRP and CA19-9 during preoperative oncological therapy predict postoperative survival in pancreatic ductal adenocarcinoma. Oncology. 2021;99(11):686–98.CrossRefPubMed
15.
Itoh S, Tsujita E, Fukuzawa K, Sugimachi K, Iguchi T, Ninomiya M, et al. Prognostic significance of preoperative PNI and CA19-9 for pancreatic ductal adenocarcinoma: a multi-institutional retrospective study. Pancreatology. 2021;21(7):1356–63.CrossRefPubMed
16.
Murakawa M, Kawahara S, Takahashi D, Kamioka Y, Yamamoto N, Kobayashi S, et al. Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection. World J Surg Oncol. 2023;21(1):263.CrossRefPubMedPubMedCentral
17.
van Wijk L, de Klein GW, Kanters MA, Patijn GA, Klaase JM. The ultimate preoperative C-reactive protein-to-albumin ratio is a prognostic factor for survival after pancreatic cancer resection. Eur J Med Res. 2020;25(1):46.CrossRefPubMedPubMedCentral
18.
Inoue D, Ozaka M, Matsuyama M, Yamada I, Takano K, Saiura A, et al. Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: a retrospective study in a single institute in Japan. Jpn J Clin Oncol. 2015;45(1):61–6.CrossRefPubMed
19.
De Felice F, Cattaneo CG, Poto GE, Antropoli C, Brillantino A, Carbone L, et al. Mapping the landscape of immunonutrition and cancer research: a comprehensive bibliometric analysis on behalf of NutriOnc Research Group. Int J Surg. 2024;110(1):395–405.CrossRefPubMed
20.
Liang X, Yao S, Lu P, Ma Y, Xu H, Yin Z, et al. The Prognostic Value of New Index (LANR) composed of pre-operative lymphocytes, Albumin, and neutrophils in patients with Resectable Colorectal Cancer. Front Oncol. 2021;11:610264.CrossRefPubMedPubMedCentral
21.
Wang S, Wang Y, Zhuang J, Wu Y, Shi W, Wang L. Prognostic significance of index (LANR) composed of preoperative lymphocytes, albumin, and neutrophils in patients with stage IB-IIA cervical cancer. PLoS ONE. 2023;18(9):e0290905.CrossRefPubMedPubMedCentral
22.
Chun YS, Pawlik TM, Vauthey JN. 8th Edition of the AJCC Cancer staging Manual: pancreas and hepatobiliary cancers. Ann Surg Oncol. 2018;25(4):845–7.CrossRefPubMed
23.
He M, Liu Y, Huang H, Wu J, Wu J, Wang R et al. Serum aspartate aminotransferase is an adverse prognostic indicator for patients with resectable pancreatic ductal adenocarcinoma. Lab Med. 2023.
24.
Jablonska B, Lampe P, Mrowiec S. The influence of nutritional status on the incidence of postoperative complications in patients following distal pancreatectomy. Prz Gastroenterol. 2020;15(1):65–75.PubMed
25.
Hu ZI, O’Reilly EM. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2023.
26.
Vezakis I, Vezakis A, Gourtsoyianni S, Koutoulidis V, Polydorou AA, Matsopoulos GK et al. An Automated Prognostic Model for pancreatic ductal adenocarcinoma. Genes (Basel). 2023;14(9).
27.
Yoon SJ, Park B, Kwon J, Lim CS, Shin YC, Jung W et al. Development of Nomograms for Predicting Prognosis of Pancreatic Cancer after Pancreatectomy: a Multicenter Study. Biomedicines. 2022;10(6).
28.
Gu Y, Hua Q, Li Z, Zhang X, Lou C, Zhang Y, et al. Diagnostic value of combining preoperative inflammatory markers ratios with CA199 for patients with early-stage pancreatic cancer. BMC Cancer. 2023;23(1):227.CrossRefPubMedPubMedCentral
29.
Huang JC, Pan B, Jiang T, Zhang XX, Lyu SC, Lang R. Effect of the preoperative prognostic nutritional index on the long-term prognosis in patients with borderline resectable pancreatic cancer after pancreaticoduodenectomy. Front Oncol. 2023;13:1098459.CrossRefPubMedPubMedCentral
30.
Sadeghi M, Keshavarz-Fathi M, Baracos V, Arends J, Mahmoudi M, Rezaei N. Cancer cachexia: diagnosis, assessment, and treatment. Crit Rev Oncol Hematol. 2018;127:91–104.CrossRefPubMed
31.
Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9:69.CrossRefPubMedPubMedCentral
32.
Danan D, Shonka DC Jr., Selman Y, Chow Z, Smolkin ME, Jameson MJ. Prognostic value of albumin in patients with head and neck cancer. Laryngoscope. 2016;126(7):1567–71.CrossRefPubMed
33.
Chen Z, Shao Y, Wang K, Cao W, Xiong Y, Wu R, et al. Prognostic role of pretreatment serum albumin in renal cell carcinoma: a systematic review and meta-analysis. Onco Targets Ther. 2016;9:6701–10.CrossRefPubMedPubMedCentral
34.
Lien YC, Hsieh CC, Wu YC, Hsu HS, Hsu WH, Wang LS, et al. Preoperative serum albumin level is a prognostic indicator for adenocarcinoma of the gastric cardia. J Gastrointest Surg. 2004;8(8):1041–8.CrossRefPubMed
35.
Asher V, Lee J, Bali A. Preoperative serum albumin is an independent prognostic predictor of survival in ovarian cancer. Med Oncol. 2012;29(3):2005–9.CrossRefPubMed
36.
De Luca R, Gianotti L, Pedrazzoli P, Brunetti O, Rizzo A, Sandini M, et al. Immunonutrition and prehabilitation in pancreatic cancer surgery: a new concept in the era of ERAS® and neoadjuvant treatment. Eur J Surg Oncol. 2023;49(3):542–9.CrossRefPubMed
37.
Liew PX, Kubes P. The Neutrophil’s role during Health and Disease. Physiol Rev. 2019;99(2):1223–48.CrossRefPubMed
38.
Zhang CL, Gao MQ, Jiang XC, Pan X, Zhang XY, Li Y, et al. Research progress and value of albumin-related inflammatory markers in the prognosis of non-small cell lung cancer: a review of clinical evidence. Ann Med. 2023;55(1):1294–307.CrossRefPubMedPubMedCentral
Metadata
Title
Prognostic significance of preoperative lymphocytes, albumin, and neutrophils (LANR) index in resectable pancreatic ductal adenocarcinoma
Authors
Jiaru Zhuang
Shan Wang
Yuan Wang
Yibo Wu
Renjing Hu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12329-z

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Clinical features of patients with carcinoma soft tissue metastases as surgical indications: a retrospective cohort study

Research

Prognostic role of macrophages and mast cells in the microenvironment of hepatocellular carcinoma after resection

Research

Prediction of the Ki-67 expression level in head and neck squamous cell carcinoma with machine learning-based multiparametric MRI radiomics: a multicenter study

Research

Estimating smoking-attributable lung cancer mortality in Chinese adults from 2000 to 2020: a comparison of three methods

Research

Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin

Research

SIRT7 promotes the proliferation and migration of anaplastic thyroid cancer cells by regulating the desuccinylation of KIF23
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits